Valeant Pharmaceuticals International, Inc.

09:49 AM EST - Valeant Pharmaceuticals International, Inc. : Announced that following the evaluation and approval of its Patient Access and Pricing Committee, the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. Valeant Pharmaceuticals International, Inc.
shares (T.VRX) are trading up $0.11 at 12.09.